Financial Data and Key Metrics Changes - GSK reported a 9% sales growth and a 19% profit growth year-to-date, reflecting strong performance in Specialty Medicines [4][10] - Excluding COVID, sales for the quarter grew 2% and 9% year-to-date, with core operating profit and core EPS growth both up 5% [5][9] - Cash generated from operations was GBP5.3 billion year-to-date, an increase of GBP0.9 billion compared to last year [52] Business Line Data and Key Metrics Changes - Specialty Medicines, the largest segment, grew 19%, driven by strong performance in oncology and HIV [19][30] - General Medicines sales increased by 7%, primarily due to Trelegy, which saw a 16% increase [35] - Vaccine sales declined by 15%, impacted by lower demand for Arexvy and Shingrix [20][21] Market Data and Key Metrics Changes - The U.S. market was significantly impacted by lower vaccine demand, while international markets showed good growth [20] - Arexvy is now launched in 35 markets, with 16 having national recommendations [22] - Shingrix's growth outside the U.S. was 9%, with U.S. penetration at 39% [23] Company Strategy and Development Direction - GSK aims for 7% to 9% sales growth and double-digit profit growth for 2024, with a focus on Specialty Medicines and Vaccines [16][57] - The company plans to pursue bolt-on business development to enhance its pipeline and technology platforms [17] - GSK is committed to delivering sustainable health impact, particularly in its HIV business, with plans to provide long-acting treatments in low and middle-income countries [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance and long-term growth outlooks, despite challenges in the vaccine segment [61][63] - The company anticipates continued growth in Specialty Medicines, particularly in oncology and respiratory treatments [30][38] - Management acknowledged potential pressures from the U.S. Inflation Reduction Act but remains optimistic about underlying demand for its products [38][94] Other Important Information - GSK has made significant progress in its pipeline, with 11 positive phase III readouts and plans for five major product launches next year [11][12] - The company reported a GBP1.8 billion charge related to the resolution of Zantac litigation, impacting operating profit [49] - GSK's net debt decreased to GBP13 billion, reflecting strong free cash generation [54] Q&A Session Summary Question: Update on pneumococcal vaccine and its timeline - Management confirmed a shift to a 30-valent vaccine for adults, with a first-in-human study expected next year [70][71] Question: Expectations for 2025 regarding Shingrix and Arexvy - Management expects 2025 to be another year of profitable growth, with continued focus on Specialty Medicines [72][74] Question: Sales contribution of Shingrix in China - GSK has sold around 240 million doses under its contract with Zhifei, with flexibility in the contract terms [90] Question: Detailed Phase III Nucala data release - Detailed data from the MATINEE trial will be presented in the first half of next year [86] Question: RSV opportunities outside the U.S. - Management indicated that the RSV vaccine is expected to see good adoption internationally, with ongoing contract negotiations [100]

Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-15170 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 GSK plc (Translation of registrant's name into English) 79 New Oxford Street, London, WC1A 1DG (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form ...

GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 9.48%. A quarter ago, it was expected that this drug developer would post earnings of $1 per share when it actually produced earnings of $1.09, delivering a surprise of 9%. Over the last four quarters, the company has surpassed ...

British pharmaceutical company GSK (NYSE: GSK ) reported its third quarter (Q3 2024) and nine months 2024 (9m 2024) results earlier today, which indicate that it's on track to achieve the full-year targets. This is even as Q3 2024 figures showed softening. Here, I Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gree ...

KEY TAKEAWAYS GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lowerthan-estimated quarterly sales and lowered its projection for vaccine sales. The company reported third-quarter sales of 8.01 billion pounds ($9.59 billion), down 2% year-over-year on lower vaccine sales and below consensus estimates of analysts polled by Visible Alpha of 8.09 billion pounds. The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease ...

-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of nonadjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while demonstrating significantly better tolerability compared to AREXVY -- -- Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 in an RSV re-vaccination setting and as part of a respiratory combination va ...

IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program MSI-High prevalence in endometrial, colorectal, and gastric cancers is ~31%, 20%, and 19%, respectively, highlighting the market potential of IDE275 (GSK959) IDEAYA to receive a $7 million payment for IND acceptance, and potential future aggregate milestones of up to $950 million. IDEAYA has a 50/50 US Profit ...

GSK plc (NYSE: GSK ) is a biopharmaceutical company with a long history of driving innovation in developing vaccines, specialty medicines, and general healthcare. The company has important products such as Shingrix and Arexvy in its vaccine segment. GSK also presents a strong My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, ...

GSK plc (GSK) announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, first-in-class oral antibiotic, gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on March 26, 2025. If approved, gepotidacin could become the first in a new class of oral antibiotic medicines to be approved for treating uUTIs in mor ...

Group 1: Novavax Update - The FDA has placed a clinical hold on Novavax's combination and standalone influenza shot [1] - Novavax's stock has dropped 17.7% to $10.36, nearing its lowest close since mid-May, although it remains up 115% in 2024 [2] Group 2: Moderna's Market Position - Moderna's shares are trading at $57.42, close to a four-year low of $55.70, reflecting a year-to-date decline of 42.2% [3] - The decline is attributed to a significant budget cut and lowered expectations for its RSV drug, with plans to regain market share by 2025 [3] Group 3: GSK Developments - GSK's stock is up 0.5% to $39.17 following the FDA's acceptance of its new drug application for urinary tract infections [4] - The company received FDA approval for its RSV vaccine in the summer, although the stock did not react significantly, and shares are 5.8% higher in 2024 [4]